Overview

Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and preliminary efficacy of three doses of Cand5. Cand5, a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF.
Phase:
Phase 2
Details
Lead Sponsor:
OPKO Health, Inc.